3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 69 points (-0.4%) at 16,384 as of Monday, March 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 999 issues advancing vs. 1,928 declining with 160 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Incyte ( INCY), down 2.5%, Novo Nordisk A/S ( NVO), down 1.4%, Vertex Pharmaceuticals ( VRTX), down 1.4%, Valeant Pharmaceuticals International ( VRX), down 1.0% and Shire ( SHPG), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry higher today. As of noon trading, Teva Pharmaceutical Industries is up $0.61 (1.2%) to $49.91 on average volume. Thus far, 2.7 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.7 million shares. The stock has ranged in price between $49.09-$49.92 after having opened the day at $49.71 as compared to the previous trading day's close of $49.30.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $47.2 billion and is part of the health care sector. Shares are up 24.3% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is up $2.87 (2.4%) to $125.13 on average volume. Thus far, 2.0 million shares of Amgen exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $122.25-$126.10 after having opened the day at $122.26 as compared to the previous trading day's close of $122.26.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $93.8 billion and is part of the health care sector. Shares are up 8.9% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Biogen Idec ( BIIB) is up $4.93 (1.5%) to $333.68 on average volume. Thus far, 657,715 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $327.01-$338.41 after having opened the day at $327.65 as compared to the previous trading day's close of $328.75.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $80.5 billion and is part of the health care sector. Shares are up 21.9% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

What Market Selloff? Dow Futures Are Popping on Sunday

What Market Selloff? Dow Futures Are Popping on Sunday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric